Welcome to our dedicated page for Charles Riv Labs Intl news (Ticker: CRL), a resource for investors and traders seeking the latest updates and insights on Charles Riv Labs Intl stock.
Charles River Laboratories International, Inc. provides products and services used in drug discovery, early-stage development, safety assessment, and the manufacture of new therapies. Company news commonly covers results from its Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions activities, along with updates on research models, nonclinical toxicology, microbial and biologics testing, and client demand trends.
Recurring developments also include digital pathology initiatives, AI-enabled workflow tools, rat in vitro fertility services, virtual control groups, and the Alternative Methods Advancement Project™, which relate to efficiency and reduced animal use where scientifically appropriate. Financial releases, investor presentations, governance updates, and portfolio changes are also recurring disclosure themes for CRL.
Charles River Laboratories (NYSE: CRL) and Medigen Vaccine Biologics Corp (MVC) have entered a collaboration focused on characterizing and validating the virus seed bank for MVC’s next-generation multivalent enterovirus vaccine. Charles River will apply its advanced analytical platforms, including cGMP-compliant Next-Generation Sequencing (NGS), to support key Chemistry, Manufacturing, and Controls (CMC) activities and IND-enabling non-clinical studies.
The partnership combines Charles River’s global biologics testing, virology, toxicology, and non-clinical development capabilities with MVC’s proven vaccine R&D and manufacturing expertise, including its ENVACGEN Enterovirus 71 vaccine approved in Taiwan and Vietnam. The companies aim to generate robust data for IND applications, enhance global regulatory readiness, and potentially extend their collaboration to additional vaccine programs targeting infectious diseases and unmet medical needs. Charles River’s acquisition of Pathoquest further strengthens its NGS-based testing offering for biopharmaceutical clients.
Charles River Laboratories (NYSE: CRL) reported second-quarter 2026 revenue of $1.00 billion, down 2.7% year over year, with 0.1% organic growth. GAAP loss per share was $(0.03), driven largely by a $63.7 million loss on CDMO and Cell Solutions divestitures, while non-GAAP EPS was $3.02, down 3.2%.
GAAP operating margin rose to 11.9% from 9.7%, and non-GAAP operating margin was 20.5%, up 420 bps sequentially but below 22.1% a year ago. The DSA and Manufacturing segments delivered modest organic growth, offset by RMS declines. Manufacturing margins expanded significantly following the CDMO divestiture.
The company raised 2026 guidance for revenue (reported decline now 3.5%–2.5% vs. 5.5%–4.0% prior) and non-GAAP EPS to $11.15–$11.45, while cutting GAAP EPS guidance to $3.05–$3.35. Charles River repurchased $100 million of stock in Q2 (total $300 million year-to-date) and completed portfolio streamlining divestitures. It also joined Eli Lilly’s TuneLab AI/ML platform, began an NGS collaboration with Arovella Therapeutics, and introduced an AI-enabled digital pathology workflow.
Charles River Laboratories (NYSE: CRL) will release its second-quarter 2026 financial results on Wednesday, August 5, before the market opens. On the same day at 9:00 a.m. ET, the company will host a conference call, with a live webcast and replay available via the Investor Relations section of its website at ir.criver.com.
Charles River (NYSE: CRL) announced a collaboration with Arovella Therapeutics (ASX: ALA) to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell bank characterization and viral safety testing supporting Arovella’s ALA-101 iNKT cell therapy platform for lymphoma and leukemia.
The U.S. FDA accepted the use of NGS for viral safety testing in Arovella’s IND, validating this approach. Charles River will also perform viral safety release testing on ALA-101 clinical batches and recently strengthened its NGS capabilities through the acquisition of Pathoquest, expanding sequencing-based testing across the biopharmaceutical development pipeline.
Charles River (NYSE: CRL) entered a collaboration with Lilly TuneLab, an AI/ML drug discovery platform created by Eli Lilly. Charles River will provide nonclinical testing services to TuneLab companies, supporting candidate down-selection, protocol standardization, and improved model learning while advancing new approach methodologies (NAMs) through its AMAP initiative.
Charles River Laboratories (NYSE: CRL) will present at two investor conferences. The company is scheduled for the William Blair 46th Annual Growth Stock Conference on June 2 at 10:00 a.m. CT (11:00 a.m. ET), and the Jefferies Global Healthcare Conference on June 3 at 9:55 a.m. ET.
Management will discuss strategic focus, business developments, and recent trends. Live webcasts and two-week replays will be available on the Investor Relations section of the Charles River website at ir.criver.com.
Charles River Laboratories (CRL) and MEDIPOST signed a strategic, non-exclusive MOU to collaborate on GMP-compliant testing and joint commercial and marketing efforts for cell therapies.
The agreement supports MEDIPOST’s global cell therapy pipeline, initially in APAC and North America, leveraging Charles River’s biologics quality control, viral and release testing expertise.
Charles River (NYSE: CRL) announced an AI-enabled, end-to-end digital pathology workflow designed to cut at least one week from standard pathology timelines while maintaining GLP standards and regulatory readiness.
The platform integrates LIMS, AI-powered slide QC, GLP-validated digital primary reviews, and decision-support tools that may boost pathologist efficiency and support 3R-aligned animal reduction through Virtual Control Groups.
Charles River Laboratories (NYSE: CRL) reported Q1 2026 revenue $995.8M, GAAP loss per share $(0.30) and non-GAAP EPS $2.06. The company completed the CDMO and Cell Solutions divestiture on May 6, 2026, repurchased $200M of stock in Q1, and reaffirmed 2026 organic revenue and non-GAAP EPS guidance.
Q1 results reflected a 1.2% reported revenue increase, a GAAP net loss driven by an $118.0M loss on assets held for sale, and lower non-GAAP operating margin vs. prior year.
Charles River (NYSE: CRL) launched commercial rat In Vitro Fertility (IVF) services on April 30, 2026, positioning itself as the first commercial provider for rat-model IVF. The service bundle includes embryo transfer, cryopreservation, rederivation, dedicated project management, optional health monitoring, and genetic validation.
Charles River says the offering aims to shorten breeding timelines, reduce animal use, recover valuable lines, expand cohorts, and maintain VAF/Elite (SOPF) health standards; streamlined quotes and timelines are available starting this quarter.